PORT-9 / AlphaTON Capital - LARVOL DELTA

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway (GlobeNewswire) - "Portage Biotech...announced that it has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists....The new assets acquired from Tarus Therapeutics include: (i) TT-10 (now PORT-6): an adenosine receptor type 2A (A2A) inhibitor to treat solid tumors. PORT-6 has received IND clearance and Portage expects to move into a Phase 1/2 clinical trial by the end of 2022 in an enriched patient population; (ii) TT-4 (now PORT-7): an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors, which has received IND clearance and which Portage plans to initiate clinical development in 2023; (iiI) TT-53 (now PORT-8): a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Portage plans to submit an IND in the near future; (iv) TT-3 (now PORT-9): a gut selective A2B inhibitor to address gastrointestinal cancers, which is currently in preclinical studies."

IND • M&A • New P1/2 trial • New trial • Gastrointestinal Cancer • Oncology • Solid Tumor